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Patients diagnosed with juvenile-onset systemic lupus erythematosus (JSLE) often have skin and oral lesions as part
of their presentation. These mucocutaneous lesions, as defined by the American College of Rheumatology (ACR) in 1997,
include malar rash, discoid rash, photosensitivity and oral ulcers. It is therefore essential to recognize mucocutaneous
lesions to accurately diagnose JSLE. The mucocutaneous lesions can be divided into those with classical histological
features (LE specific) and those strongly associated with and forming part of the diagnostic spectrum, but without the
classical histological changes of lupus (LE nonspecific). A malar rash is the most commonly associated LE specific
dermatological presentation. This skin manifestation is an acute form and also correlates with disease activity.
Subacute (polycyclic or papulosquamous lesions) and chronic (discoid lesions) forms, whilst showing classical
histological changes supportive of lupus, are less commonly associated with systemic lupus and do not correlate
with disease activity. The most commonly associated skin lesions without classical lupus changes are cutaneous
vasculitis, oral ulcers and diffuse non-scarring alopecia. These signs frequently relate to disease activity. An understanding
of cutaneous signs and symptoms of lupus in children is important to avoid delay in diagnosis. They will often improve
as lupus is adequately controlled and their reappearance is often the first indicator of a disease flare.
Keywords: Juvenile-onset systemic lupus erythematosus, Mucocutaneous lupus lesions, Lupus erythematosus specific
lesions, Lupus erythematosus nonspecific lesions, Diagnosis, TreatmentIntroduction
Juvenile-onset systemic lupus erythematosus (JSLE) is one
of the most common systemic autoimmune connective
tissue disorders in children. The disease severity varies
from mild to severe, and requires long term and often
aggressive treatment. It is estimated that 15-20% of SLE
patients develop signs and symptoms during childhood
and adolescence [1-3].
The incidence of JSLE across the world varies between
0.3 to 0.9 per 100,000 per year with estimated prevalence
between 0.3 to 8.8 per 100,000 [4-7]. Females are more
likely to be affected (male and female ratio; 1:3 to 1:5) with
the peak age of presentation around puberty (median age* Correspondence: m.w.beresford@liverpool.ac.uk
1Institute of Translational Medicine, Alder Hey Children’s NHS Foundation
Trust, University of Liverpool, Liverpool, UK
5Department of Women’s and Children’s Health, Institute of Translational
Medicine, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool
L12 2AP, UK
Full list of author information is available at the end of the article
© 2015 Chiewchengchol et al.; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.onset 12.1) [8-10]. The clinical presentation of JSLE is fre-
quently more severe than adult onset SLE with multiple
organ involvement, particularly the kidney and central
nervous system [11-18].
The diagnosis of JSLE is made in accordance with the
American College of Rheumatology classification (revised
criteria 1997) [19], although recent modifications to these
criteria have been proposed [20]. The ACR criteria include
several mucocutaneous manifestations: malar (butterfly)
rash; discoid rash; photosensitivity and oral ulcers.
Patients will often present with skin and oral lesions as
initial clinical manifestations of the disease. It is therefore
important to recognize these mucocutaneous manifesta-
tions of the disease.
In adults, it is common to have limited manifestations
of lupus affecting just the skin without fulfilling the ACR
diagnostic criteria. This is in contrast, to lupus skin lesions
in children which are usually associated with systemicd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ous aspects of JSLE.
Review
Epidemiology
Mucocutaneous manifestations are very common in both
adult and JSLE (60-85%) [22]. When considering the ACR
diagnostic criteria, dermatological manifestations occur
second to involvement of the hematological (50-100%)
and musculoskeletal systems (60-90%) [22,23]. The most
common mucocutaneous lesions in JSLE are: malar rash,
photosensitivity, cutaneous vasculitis and oral or nasal ul-
cers. Others include generalized lupus rash, non-scarring
alopecia, livedo reticularis and Raynaud’s phenomenon.
Although the prevalence of mucocutaneous manifesta-
tions in paediatric and adult patients are quite similar,
some lesions are clearly less common in children; such
as subacute cutaneous lesions, a discoid rash and livedo
reticularis [2,23-28]. Table 1 summarizes the compara-
tive frequency of mucocutaneous manifestations in JSLE
and adult SLE. In JSLE, lupus specific mucocutaneous
manifestations appear more frequently [29].
Classifications and clinical manifestation
The classifications of mucocutaneous manifestations were
first developed in the 1970s [27] and are divided into 2
categories; lupus erythematosus specific skin lesions (LE
specific), and nonspecific skin lesions (LE nonspecific).
This classification is used in both juvenile and adult onsetTable 1 Comparative frequency of mucocutaneous lesions
in juvenile systemic lupus erythematosus (JSLE) and
adult systemic lupus erythematosus (adult SLE)
Mucocutaneous lesions JSLE Adult SLE
1. LE specific skin lesions
Malar rash 44-85% [2,5,6] 40-52% [5,6]
Generalized lupus rash 30% [28] N/A [5,6]
Subacute cutaneous LE Rare [8,33,34] 7-27% [8,9]
Discoid rash <10% [1,2,4,18,28,29] 20-50% [5,36]
Generalized DLE 10-37% [31,34-36] 40-49% [36]
Lupus panniculitis/
profundus
<1% [34,37] 1-3% [10]
2. LE nonspecific skin lesions
Cutaneous vasculitis 16-45% [11,21,47] 11-70% [5,7,12,13]
Photosensitivity 35-50% [2,4,5] 63% [7]
Oral and nasal ulcers 20-40% [2,4,5,49,52] 18-30% [6,7,49,52]
Non-scarring alopecia 15-30% [2,5] 25-55% [2,5,53]
Livedo reticularis 6-12% [14,30,33] 22-35% [12]
Raynaud’s phenomenon 6-12% [15,16] 10-45% [15,16,60,61]
Bullous SLE <1% [28] N/A [62-64]
N/A; A lack of published evidence for the relative frequency of these lesions.forms of the disease and most of these appear similarly in
both age groups. This review will highlight any differences
between the two age groups.
Specific mucocutaneous lesions
These lesions are categorized into 3 forms.
Acute cutaneous lupus erythematosus (ACLE) ACLE
presents with localized or generalized lesions and they
are very sensitive to ultraviolet light. Localized ACLE or
malar (butterfly) rash is the most common LE specific
lesion in both JSLE and adult SLE patients [23,30,31]. It is
characterized by a well defined, symmetrical erythematous
and edematous, non-pruritic malar rash, over the nasal
bridge and typically sparing the nasolabial folds (Figure 1A
and B). Lesions may also involve the ears and may mimick
an interface dermatitis (Figure 1C). They typically resolve
with post-inflammatory hypo/hyperpigmentation. Less
frequently, lesions in ACLE are a more diffuse rash in-
volving non-light exposed sites, often with extensive
erythema and edema (Figure 1D). Both the localized
malar rash and the more diffuse erythema are strongly
related to systemic disease activity in JSLE and adult
SLE [23,30,31].
Subacute cutaneous lupus erythematosus (SCLE) SCLE
is extremely rare in JSLE patients [32], but more com-
mon in adult SLE patients. There are two forms: annu-
lar/polycyclic lesions and papulosquamous/psoriasiform
lesions in adults and both forms are found in JSLE pa-
tients. The lesions are characterized as widespread, sym-
metrical, erythematous papules/plaques, with scales and
telangiectasia on sun-exposed and non-sun-exposed
areas, such as the chest and back. They are particularly
common on the face and upper extremities and usually
heal without scaring [32]. Skin involvement in of the
lower extremities is rare in adults but is more common
in children [33].
Numerous cases of drug-induced SCLE have been re-
ported in adults such as antihypertensive drugs, anticon-
vulsants and antihistamines [29]. As the clinical features
of drug-induced SCLE lesions cannot be reliably differen-
tiated from SCLE lesions, any suspected drugs should be
discontinued but these are seldom used in childhood.
Chronic cutaneous lupus erythematosus (CCLE) In
adults, it is common to see discoid lupus on the skin
without underlying systemic involvement. This is a rare
presentation in children particularly below the age of 10
[12,22,23,26]. Discoid lupus has rarely been reported in
children without systemic symptoms [28,33,34]. These
lesions occur most commonly on the scalp (vertex),
face and ears. The lesions usually occur above the neck
as scarring indurated, purplish papules, expanding into
coin-shapes with atrophic formation and telangiectasia. If
A B
C D
Figure 1 LE specific skin lesions: (A) Malar (butterfly) rash (mild symptom); (B) Malar rash with interface dermatitis; (C) Crusting and
interface changes affecting the ear; and (D) Generalized ACLE or maculopapular lupus rash at both knees.
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Follicular plugging usually occurs because an adherent
scale becomes stuck to the hair follicles. Interestingly,
the risk of progression from DLE to SLE is much higher
in children than in adults (23.5-26% VS 5-10%). The risk
seems to be greater in children with a family history of
autoimmune rheumatic disease [28,34]. Generalized DLE
(above and below the neck) in children is described in sev-
eral studies and appears to be associated with a worse
prognosis [28,33-35].
Other forms of CCLE are rare in children, such as lupus
panniculitis and lupus profundus [33,36], mucosal LE and
chilblain LE [37-40], and tumid LE [41-43]. Lupus erythe-
matosus/lichen planus overlap syndrome has been only
reported in adults [44,45].
Nonspecific mucocutaneous lesions
The key difference between these nonspecific skin mani-
festations in lupus compared to the lupus specific mani-
festations, is that they appear not only in JSLE, but alsoin other inflammatory diseases. Most LE nonspecific le-
sions commonly found in children and adults are similar
and both affect vasculature (e.g. cutaneous vasculitis,
livedo reticularis and Raynaud’s phenomenon). The other
common lesions are photosensitivity, oral ulcers and dif-
fuse non-scarring alopecia.
Cutaneous vasculitis Cutaneous vasculitis usually af-
fects small blood vessels (leukocytoclastic vasculitis).
The lesions are characterized as petechiae or palpable pur-
pura (Figure 2A), and may occasionally blister. They are
commonly found on the face, palms and soles of the feet
(Figure 2B). The lesions are induced by the formation of
immune complexes and neutrophilic infiltration, and the
presence of vasculitic lesions strongly relates to systemic
disease activity [46]. Other clinical presentations include:
punctate lesions and urticarial vasculitis (Figure 2C).
Photosensitivity Photosensitivity can appear as any skin




Figure 2 LE nonspecific skin lesions: (A) Vasculitic purpura at left palm; (B) Cutaneous vasculitis at right cheek, eyelid and nose; (C)
Cutaneous urticarial vasculitis at right palm; (D) Oral discoid lesion on the lateral border of the tongue; and (E) Oral ulceration and a
discoid lesion on the hard palate.
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lesion occurs on sun-exposed areas (such as the face,
upper chest, or extremities) and becomes progressively
worse after sun-exposure. Although the lesions usually
develop during active disease, it is unknown if they cor-
relate with systemic disease. Photosensitivity with malar
rash is commonly found in juvenile dermatomyositis;
thus, other lupus features are needed in order to differ-
entiate between the two conditions [47].
Oral or nasopharyngeal ulcers There are two types of
these ulcers: those with classical LE histological changes
representing oral discoid lesions (Figure 2D) and non-
specific ulcers in keeping with aphthous ulceration [48].
The lupus specific lesions begin with solitary erythema
and hemorrhaging patches before developing into dis-
coid ulcers with a reticulate border. Typically, the lesions
are painless and located on the hard palate (Figure 2E).
In contrast, the nonspecific aphthous ulcers are usually
painful, with multiple lesions on the buccal mucosa, lipsand nasal septum, whilst also having a tendency to bleed
[49,50]. Oral and nasopharyngeal ulcers are normally
found during active disease and subside with disease re-
mission in JSLE and adult SLE patients [30,48,51].
Diffuse non-scarring alopecia Alopecia often presents
with generalized hair loss without signs of inflammation
on the scalp. Diffuse, non-scarring alopecia in JSLE and
adult SLE patients usually suggests active disease [52].
However, it may occur three months after a severe lupus
flare; e.g. Telogen effluvium, which is a nonspecific finding
and can also occur after any significant systemic disturb-
ance [53]. Other forms of alopecia also found in JSLE pa-
tients include lupus hair (thin and weakened hair at the
periphery of the scalp), patchy non-scarring alopecia (mild
erythematous, scattered patchy hair loss) and alopecia
areata [54].
Livedo reticularis These lesions present more commonly
in both juvenile and adult patients who are diagnosed
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by erythematous or cyanotic discoloration of the skin
with reticulated (net-like) pattern, usually on the lower
extremities. The etiology and correlation with systemic
disease activity are unknown, but vascular obstruction
and blood viscosity may be the cause [56].Raynaud’s phenomenon Raynaud’s phenomenon is
characterized by the classic “triphasic” color changes
limited to the digits; pallor (white or blanching) followed
by the cyanosis (blue) then erythema (red or reactive
hyperemia). This color change sequence results from exces-
sive vasospasms triggered by cold exposure or emotional
stress, and can often be reversed following re-warming.
There is no evidence to suggest that this symptom corre-
lates with systemic disease [57,58].Bullous SLE The bullous lesions are rare and most com-
monly reported in young adults and African-American
women [59]. It is characterized by multiple, tense vesicles/
bullae usually on face, neck and upper trunk. As bullous
SLE is similar to other vesicobullous conditions, the cri-
teria needed to make a diagnosis are: (a) acquired wide-
spread cutaneous vesicobullous lesions; (b) subepidermal
blister with acute neutrophilic infiltration in dermis con-
firmed by histopathology; (c) evidence of IgG at the der-
mal side of the basement membrane zone by direct or
indirect immunofluorescence; (d) presence of antibodies
to collagen type VII by indirect immunofluorescence on
salt-split skin and (e) a tendency to respond to Dapsone
[60]. There is no evidence of any correlation between bul-
lous SLE and systemic disease activity [61].Other LE nonspecific lesions Other lesions include:
calcinosis cutis, acanthosis nigricans, hypocomplementae-
mic urticarial vasculitis (very rare in JSLE patients) [62-64],
whilst rheumatoid nodules, anetoderma and erythromelal-
gia have been reported in adult SLE [65-67].Diagnosis of cutaneous lupus
Careful clinical assessment at presentation is usually
sufficient to make a diagnosis of mucocutaneous lupus
lesions. Skin histopathology may be useful, but this
needs to be carefully considered in children because of
scarring after this procedure. Laboratory investigations
in JSLE based on the ACR criteria can also guide and
support the diagnosis of the affected lesions in patients
diagnosed with JSLE. Moreover, some of these findings
are more commonly associated with particular lesions;
for example, anti-Ro/SSA is often detected in JSLE patients
presenting with SCLE [32].Histopathology
Histopathological findings of the affected lesions of JSLE
and adult SLE usually show similarities. Characteristically,
skin histopathology of a LE specific lesion is interface
dermatitis with basement membrane damage. Mild to
severe inflammation is present in the dermis and skin
appendages with perivascular lymphocytic and neutrophil
infiltrates called leukocytoclastic vasculitis [68-70]. Abun-
dant extracellular deposition of mucin is markedly ob-
served in the dermis between the collagen bundles and
sweat glands [68-70]. In particular, skin histopathology of
DLE shows classical features: vacuolar degeneration of
basal cell layer; thickened basement membrane; orthoker-
atosis with follicular plugging in upper dermis. Epidermal
atrophy with marked thickening of basement membrane
occurs in the later stages. Dermal fibrosis and follicular
atrophy with abundant extracellular mucin deposits be-
tween collagen bundles in reticular dermis and sweat
glands are eventually seen [68-70].
The histopathology features attributed to nonspecific
lupus vary depending on the type of lesions and are not
pathognomonic of the condition. For example, cutaneous
vasculitis in JSLE shows small vessel leukocytoclastic vas-
culitis including endothelial cell damage, fibrin deposition,
inflammatory cell infiltrate (predominantly neutrophils)
and nuclear dust. These findings can be found in juvenile
patients with other systemic diseases such as henoch-
schönlein purpura, juvenile dermatomyositis and systemic
juvenile idiopathic arthritis [71].
Immunofluorescence findings
Immunofluorescence is not routinely used for the diagnosis
in JSLE patients with mucocutaneous lesions, but it can be
helpful when supporting evidence for making a diagnosis
is needed. Direct immunofluorescence shows band-like
deposits of IgG, IgM and complement factor (C3) in the
basement membrane zone or dermo-epidermal junction
(lesional lupus band test) [72]. However, false positive
findings can occur especially in sun-exposed areas. Im-
mune deposits are also found in non-lesional skin biopsies
(non-lesional lupus band test).
Management
Careful assessment of systemic disease status is first needed,
as inducing disease remission will lead to resolution of the
mucocutaneous lesions. Treatment is tailored to disease se-
verity and organ involvement. In limited cutaneous disease,
topical corticosteroids may be helpful. In more extensive
disease or where there is systemic involvement, short
courses of systemic corticosteroids with concurrent use of
hydroxychloroquine and/or immunosuppressive therapies
are indicated. Table 2 summarizes the commonly used
treatments of mucocutaneous lesions and their common
side effects in JSLE patients.
Table 2 Summary of commonly used treatment in mucocutaneous lupus lesions in juvenile systemic lupus
erythematosus (JSLE) [74-81]
Treatments Dose Indications Common/serious side effects
1. Topical
Sunscreen 2 mg/cm2, SPF >30 All sun-exposure areas apply at least
30 min before sun exposure
Greasy and allergic contact dermatitis
Topical steroids
- Mild potency 1% hydrocortisone acetate Eyelids, face and intertriginous areas Hypopigmentation, skin atrophy, increased
hair growth and telangiectasia;
- Moderate potency 0.1% triamcinolone acetonide Scalp and body
0.1% mometasone furoate
- High potency 0.05% clobetasone propionate Scalp, palms and soles
0.05% betamethasone dipropionate
Intralesional steroids 2.5-10 mg/mL Discoid lesions particularly on scalp Skin atrophy and hypopigmentation
Calcineurin inhibitors 1% pimecrolimus Eyelids, face and intertriginous areas
(steroid-sparing effects)
Burning sensation and infection
0.03%, 0.1% tacrolimus
2. Systemic
Systemic Steroids 0.5-2 mg/kg ideal body weight per
day between 2–4 weeks, followed
by tapering dose
Severe skin lesions or systemic disease
flare up
Osteoporosis, cushing syndrome and
growth retardation
Hydroxychloroquine
- Children 5 mg/kg ideal body weight per day Combination with systemic steroids Ocular toxicity, gastrointestinal upset,
dizziness and headache
(steroid-sparing effects)- Young adults 6-6.5 mg/kg ideal body weight per day
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Mucocutaneous lupus lesions are generally highly photo-
sensitive, triggered by both UVA and UVB [73]. Children
are advised to avoid prolonged sun exposure and rou-
tinely wear protective clothing (including hats). Very po-
tent physical and chemical sunscreens include: titanium
dioxide, zinc oxide, tocopheryl acetate and flavonoids.
These can be used in children, particularly before direct
sun exposure. Children in tropical countries may have
some difficulties of sun avoidance; thus, parents as well as
school teachers are encouraged to be vigilant about UV
protection. Lack of sun exposure in affected individuals
can sometimes result in low vitamin D levels; if so, vitamin
D3 and calcium supplements should be considered [74].
Corticosteroids
Topical corticosteroids are commonly used in JSLE pa-
tients as they are very effective for mucocutaneous lupus
lesions [74]. High potency corticosteroids are necessary
to induce remission of the lesions. This can then be
followed by gradual tapering of the dose to discontinu-
ation. Mild to moderate potency corticosteroids are usu-
ally applied to lesions on the face and body. However,
calcineurin inhibitors are preferred in delicate areas (e.g.
around the eyes, groin and genitalia) for more prolonged
use to prevent skin thinning. If the lesions are part ofJSLE, then they will only be improved along with the
systemic therapies used to control the disease. In this
group, treatments should be more focused on control-
ling the systemic disease.
An intralesional corticosteroid injection can be used in
adolescents with DLE, particularly on the scalp, to
minimize the scarring alopecia [75], whilst systemic cor-
ticosteroids are very helpful in the short term of induce
remission of severe mucocutaneous lesions (e.g. multiple
oral ulcers, or severe cutaneous vasculitis with ulceration
and necrosis). However, these should be avoided for
prolonged periods due to serious side effects [76].
Therefore, the affected areas, the route of administra-
tion, the potency of corticosteroids, length of treatment
and any side effects should be carefully considered, par-
ticularly in JSLE patients.Aminoquinolone antimalarial drugs
Hydroxychloroquine demonstrates good efficacy with
mucocutaneous lupus lesions and is therefore the first
line treatment when systemic therapy is required [21].
The mechanism of action of these drugs is uncertain but
includes Toll-Like Receptor blockade that prevent anti-
gen stimulation, a process thought to be involved in the
pathogenesis of the disease [77]. Serious side effects in
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careful consideration as they depend on the maximum
daily dose rather than the cumulative dose. Therefore,
using the ideal body weight for calculation of the daily
dose in children is important [78]. Routine eye check-ups
is recommended.
Other medications
Topical calcineurin inhibitors, such as tacrolimus and
primecrolimus, are useful for lesions that are particularly
sensitive to topical corticosteroids and prone to skin
atrophy, such as on the eyelids, face and intertriginous
areas and are well-tolerated [79-81]. Steroid sparing im-
munosuppressive agents in JSLE patients (e.g. methotrex-
ate, azathioprine and mycophenolate mofetil), are usually
initiated along with hydroxychloroquine [74].
Conclusion
Patients with JSLE commonly present with mucocutaneous
manifestations, and it is therefore important to recognize
the lesions to make an accurate diagnosis. Assessment of
systemic disease status in any child presenting with muco-
cutaneous lupus features is crucial as it may take a number
of years to meet the diagnostic criteria. Therefore, any child
with mucocutaneous lesions associated with SLE needs to
be regularly reassessed and monitored. Sun protection is
vital and should be encouraged to prevent both worsening
of the symptoms and exacerbation of SLE. In adult patients,
lupus associated skin disease is often localized. In children,
lesions are usually associated with systemic disease and re-
quire treatment with systemic immunosuppressive drugs in
order to achieve adequate disease control.
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